Efzofitimod Phase 3 Protocol Submitted: First-in-Class Sarcoidosis Bet With No Mechanistic Precedent

aTyr Pharma Awaits FDA Response for Planned Efzofitimod Phase 3 Study

aTyr Pharma announced an update on the anticipated timing of the U.S. Food and Drug Administration's (FDA) response regarding the protocol for its planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company expects to receive the FDA's feedback by mid-September 2026, following the protocol submission in June 2026. The planned global, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of efzofitimod, dosed intravenously at 5.0 mg/kg every three weeks for 17 doses, in approximately 372 patients over 54 weeks. The primary endpoint is the change from baseline in forced vital capacity at week 48.

• aTyr Pharma is awaiting a regulatory response from the FDA by mid-September 2026 concerning the protocol for its planned Phase 3 study of efzofitimod. This follows the submission of the protocol in June 2026 for the investigation of efzofitimod in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease.
• The upcoming Phase 3 trial is designed as a global, randomized, double-blind, placebo-controlled study. It will assess the efficacy and safety of efzofitimod in up to approximately 372 patients over a 54-week period, with participants receiving 5.0 mg/kg efzofitimod or placebo intravenously every three weeks for a total of 17 doses.
• The primary endpoint for the planned study is the change from baseline in forced vital capacity (FVC) at week 48. A key secondary endpoint will measure the change from baseline in the King’s Sarcoidosis Questionnaire-Lung score at week 48. The study targets patients with symptomatic pulmonary sarcoidosis with restrictive lung disease who are on stable doses of corticosteroids or immunosuppressants.

The Persistent Challenges in Treating Pulmonary Sarcoidosis

The management of pulmonary sarcoidosis is complicated by its highly variable clinical course, the absence of consensus-driven treatment protocols, and the risk of significant long-term harm from the therapies most commonly employed. These challenges are compounded in patients with restrictive lung disease, where progressive fibrosis and associated complications narrow the therapeutic window considerably.

• Absence of treatment consensus and evidence gaps: There is no consensus about when to start treatment, what dose of steroids to give, or for how long. Evidence from randomized controlled trials supporting the use of immunosuppressive and cytotoxic agents is limited, and data on lung function, chest X-ray, and dyspnea from these trials are largely inconclusive.

• Limited long-term disease-modifying effect of corticosteroids: Although oral corticosteroids improve chest X-ray appearance over 3–24 months, little evidence was found of improvement in lung function or of any long-term disease-modifying effect. Inhaled corticosteroids improved symptoms in one small study but not lung function or chest X-ray.

• Corticosteroid toxicity and the steroid-sparing challenge: Corticosteroid-related adverse events are a recognized concern, particularly with long-term use. Steroid-sparing anti-sarcoidosis agents take longer to act and are associated with unique but mostly reversible toxicities. Treatment studies for sarcoidosis-associated progressive pulmonary fibrosis have been underpowered to demonstrate clear-cut benefit of anti-fibrotic agents.

• Progressive fibrosis and advanced disease: Approximately 20% of patients progress to advanced pulmonary sarcoidosis, driven mostly by pulmonary fibrosis and associated complications including bronchiectasis, chronic pulmonary aspergillosis, and pulmonary hypertension. The natural history of advanced pulmonary sarcoidosis is largely unknown and evidence-based treatment guidelines are lacking.

• Refractory and relapsing disease: A small proportion of patients are refractory to conventional immunosuppressants. In renal sarcoidosis, relapses occurred in 48% of patients, often during or after tapering of corticosteroids, and no baseline factors predicted relapse risk — underscoring the broader challenge of identifying predictive markers for response and relapse across sarcoidosis phenotypes.

• Heterogeneity of clinical course and individualized management: Treatment of sarcoidosis must be individualized for each patient due to the heterogeneity of the clinical course, comorbid conditions, response to therapy, and tolerance of medication side effects, making the development of standardized protocols particularly difficult.

Efzofitimod's Planned Phase 3 Study Design and Endpoints

Several clinical studies have examined pulmonary sarcoidosis with varying degrees of lung function impairment, evaluating both disease-modifying interventions and health-related quality of life instruments. The trials below represent key investigations relevant to study design parameters and endpoints in this population.

The knowledge base does not have sufficient information on this aspect.

Efzofitimod's Broader Development Across Interstitial Lung Diseases

Beyond pulmonary sarcoidosis, efzofitimod is under investigation across a broader spectrum of interstitial lung diseases (ILDs), reflecting the wide immunomodulatory potential of its mechanism of action via neuropilin-2 (NRP2) targeting. The preclinical programme has evaluated efzofitimod across multiple distinct ILD models, providing the translational rationale for expanded clinical development.

• Bleomycin-induced lung injury model: Efzofitimod was assessed in a bleomycin treatment animal model, where it demonstrated reductions in lung inflammation, immune cell infiltration, and fibrosis.

• Silicosis model: Efzofitimod was evaluated in a silicosis animal model, again showing reductions in lung inflammation, immune cell infiltration, and fibrosis.

• Chronic hypersensitivity pneumonitis model: Efzofitimod was trialled in an animal model of chronic hypersensitivity pneumonitis, with observed reductions in lung inflammation, immune cell infiltration, and fibrosis.

• Systemic sclerosis-associated ILD model: Efzofitimod was studied in a systemic sclerosis animal model, demonstrating reductions in lung inflammation, immune cell infiltration, and fibrosis.

• Rheumatoid arthritis-ILD model: Efzofitimod was evaluated in a rheumatoid arthritis-ILD animal model, with reductions in lung inflammation, immune cell infiltration, and fibrosis observed.

The knowledge base does not have sufficient information on this aspect. regarding the specific intervention models (e.g., single-arm, randomised controlled) for any ongoing clinical trials in these non-sarcoidosis ILD indications beyond the preclinical animal model data described above.

Charting the Course for a Novel Sarcoidosis Therapy

The journey toward new therapeutic options for pulmonary sarcoidosis, a chronic and often debilitating interstitial lung disease, is marked by significant unmet needs. Current treatments, primarily corticosteroids, come with substantial side effects, and other biologics have shown only modest efficacy. In this context, efzofitimod, a novel immunomodulator targeting neuropilin 2 (NRP2), represents a promising advancement.

This first-in-class biologic, derived from a naturally occurring splice variant of histidyl-tRNA synthetase, has demonstrated a unique mechanism of action by downregulating immune responses and resolving inflammation and fibrosis in preclinical models. Early clinical data from Phase 1b/2a studies have been encouraging, showing efzofitimod to be safe and well-tolerated, with dose-dependent improvements in steroid reduction and patient-reported quality of life, alongside a trend toward improved lung function. These findings, supported by exposure-response analyses, have paved the way for a pivotal Phase 3 study.

The strategic implications of efzofitimod's continued development are clear. If successful, it could establish a new standard of care, offering a disease-modifying therapy that addresses the underlying pathology of sarcoidosis more effectively than current options. However, the path forward is not without its challenges:

• The large Phase 3 trial must definitively confirm the preliminary efficacy signals, particularly for the primary endpoint of forced vital capacity (FVC), which showed only a non-significant trend in earlier, smaller studies.

• The extended timeline for FDA feedback on the Phase 3 protocol underscores the rigorous regulatory scrutiny for novel agents in this space, indicating potential for further delays or required protocol adjustments.

• Demonstrating a clinically meaningful and statistically significant improvement in lung function, beyond the modest effects seen with other biologics, will be critical for market differentiation and adoption.

Despite these considerations, the progression of efzofitimod into Phase 3 represents a significant step forward for patients with pulmonary sarcoidosis. The upcoming FDA feedback on the protocol will be a crucial milestone, shaping the trajectory of this potentially transformative therapy and offering a new hope in a landscape hungry for innovation.